Feasibility of next-generation sequencing in clinical practice: results of a pilot study in the Department of Precision Medicine at the University of Campania 'Luigi Vanvitelli'
Open Access
- 1 March 2020
- journal article
- research article
- Published by Elsevier BV in ESMO Open
- Vol. 5 (2), e000675
- https://doi.org/10.1136/esmoopen-2020-000675
Abstract
Background The emerging role of next-generation sequencing (NGS) targeted panels is revolutionising our approach to cancer patients, providing information on gene alterations helpful for diagnosis and clinical decision, in a short time and with acceptable costs. Materials and methods In this work, we evaluated the clinical application of FoundationOne CDx test, a hybrid capture-based NGS. This test identifies alterations in 324 genes, tumour mutational burden and genomic signatures as microsatellite instability. The decision to obtain the NGS assay for a particular patient was done according to investigator's choice. Results Overall, 122 tumour specimens were analysed, of which 84 (68.85%) succeeded. The success rate was influenced by type of specimen formalin-fixed paraffin embedded (FFPE block vs FFPE slides), by origin of the sample (surgery vs biopsy) and by time of fixation (= 5 years). The most frequent subgroups of effective reports derived from colorectal cancer (25 samples), non-small-cell lung cancer (16 samples), ovarian cancer (10 samples), biliary tract cancer (9 samples), breast cancer (7 samples), gastric cancer (7 samples). The most frequent alterations found in whole population referred to TP53 (45.9%), KRAS (19.6%) and APC (13.9%). Furthermore, we performed an analysis of patients in whom this comprehensive genomic profiling (CGP) had a relevance for the patient's disease. Conclusions On our opinion, CGP could be proposed in clinical practice in order to select patients that could most benefit from the analysis proposed, like patients with good performance status without any available treatments or with unexpected resistance to a therapy.Funding Information
- Regione Campania Cancer Research Campaign I-Cure Grant
This publication has 36 references indexed in Scilit:
- A Canadian Guideline on the Use of Next-Generation Sequencing in OncologyCurrent Oncology, 2019
- Applications and analysis of targeted genomic sequencing in cancer studiesComputational and Structural Biotechnology Journal, 2019
- The emerging clinical relevance of genomics in cancer medicineNature Reviews Clinical Oncology, 2018
- A systematic analysis of FDA-approved anticancer drugsBMC Systems Biology, 2017
- Twenty-First Century Precision Medicine in Oncology: Genomic Profiling in Patients With CancerMayo Clinic Proceedings, 2017
- Comprehensive genomic profiling in routine clinical practice leads to a low rate of benefit from genotype-directed therapyBMC Cancer, 2017
- Implementing Genome-Driven OncologyCell, 2017
- Clinical Actionability of Comprehensive Genomic Profiling for Management of Rare or Refractory CancersThe Oncologist, 2016
- Enabling a Genetically Informed Approach to Cancer Medicine: A Retrospective Evaluation of the Impact of Comprehensive Tumor Profiling Using a Targeted Next-Generation Sequencing PanelThe Oncologist, 2014
- Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencingNature Biotechnology, 2013